amprenavir + abacavir + lamivudine

**amprenavir + abacavir + lamivudine** is an oral fixed-dose combination of three antiretroviral drugs used as part of combination antiretroviral therapy (cART) for the treatment of HIV-1 infection. Amprenavir is a protease inhibitor that prevents HIV-1 protease from processing viral polyproteins, thus blocking the maturation of infectious viral particles[4]. Abacavir and lamivudine are both nucleoside reverse transcriptase inhibitors (NRTIs); they act as synthetic analogues of natural nucleosides and terminate viral DNA synthesis by inhibiting HIV reverse transcriptase and incorporating into viral DNA, blocking chain elongation[5][6][7][2][8][9]. This combination acts synergistically to suppress HIV replication and slow immunodeficiency progression, but is not curative.